Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study

Benjamin A. Fisher(University Hospitals Birmingham NHS Foundation Trust), Antónia Szántó(University of Debrecen), Wan‐Fai Ng(Newcastle upon Tyne Hospitals NHS Foundation Trust), Michele Bombardieri(Queen Mary University of London), Maximilian Posch(Charité - Universitätsmedizin Berlin), Athena Papas(Tufts University), Arwa M. Farag(Tufts University), Thomas Daikeler(University Hospital of Basel), Bettina Bannert(University Hospital of Basel), Diego Kyburz(University Hospital of Basel), Alan Kivitz(Altoona Center for Clinical Research), Steven E. Carsons(Winthrop-University Hospital), David Isenberg(University College Hospital), Francesca Barone(University Hospitals Birmingham NHS Foundation Trust), Simon Bowman(University Hospitals Birmingham NHS Foundation Trust), Pascal Espié(Novartis (Switzerland)), David Floch(Novartis (Switzerland)), Cyrielle Dupuy(Novartis (Switzerland)), Xiaohui Ren(Novartis (Switzerland)), P. Faerber(Novartis (Switzerland)), A. Wright(Novartis (Switzerland)), Hans Hockey, Michael Rotte(Novartis (Switzerland)), Julie Milojevic(Novartis (Switzerland)), Alexandre Avraméas(Novartis (Switzerland)), Marie‐Anne Valentin(Novartis (Switzerland)), James S. Rush(Novartis (Switzerland)), P Gergely(Novartis (Switzerland))
The Lancet Rheumatology
January 23, 2020
Cited by 121

Abstract


Related Papers

No related papers found

Powered by citation graph analysis